Haemonetics Corporation — FY2012 Form 10-K
Reporting period: Fiscal year ended March 31, 2012 (52 weeks). Although the request metadata refers to 2011 Q4, this filing reports the full FY2012 year; it also presents quarterly data, including FY2012 fourth-quarter results.
Business context
Haemonetics develops blood-management devices, single-use consumables, software, and consulting services for plasma collectors, blood centers, and hospitals. It reports as one operating segment. Consumables and equipment-use fees generated approximately 81.7% of revenue. Sales were generated in more than 97 countries; 51.6% of revenue came from outside the United States.
Financial performance
| Metric | FY2012 | FY2011 | Change |
|---|---|---|---|
| Revenue | $727.8 million | $676.7 million | +7.6% |
| Gross profit / margin | $369.2 million / 50.7% | $355.2 million / 52.5% | Profit +4.0%; margin down 1.8 points |
| Operating income / margin | $88.8 million / 12.2% | $110.5 million / 16.3% | −19.7% |
| Net income | $66.9 million | $80.0 million | −16.4% |
| Diluted EPS | $2.59 | $3.12 | −17.0% |
| Operating cash flow | $115.3 million | $123.5 million | −$8.1 million |
Revenue growth was 5.6% excluding favorable foreign-exchange effects. Product quality costs, sales mix (more lower-margin plasma disposables and fewer higher-margin hospital products), and higher freight costs pressured gross margin. Operating expenses rose 14.6%, including restructuring, R&D and sales investment, acquisition transaction costs, and expenses related to the HS Core quality matter.
Plasma disposables grew 13.6%; platelet disposables 7.5%; diagnostics 18.9%; OrthoPAT disposables fell 12.5%, largely due to a voluntary device recall. Software solutions revenue rose 5.5%, after strong acquisition-driven growth in FY2011.
Liquidity, debt, and capital allocation
- Cash and cash equivalents were $228.9 million at year-end, versus $196.7 million a year earlier; working capital was $396.4 million and the current ratio was 4.0.
- Total debt was $3.8 million, mainly a real-estate mortgage. Net cash was $225.1 million.
- Capital expenditures were $53.2 million. Cash used for share repurchases was $50.0 million; approximately 0.9 million shares were repurchased.
- Operating cash flow was lower, principally reflecting higher receivables and inventory and lower net income. Inventory increased to $117.2 million from $84.4 million.
Outlook, material developments, and risks
- Management expected plasma collection growth to moderate in FY2013; recent plasma contract renewals included price decreases. Japanese Red Cross purchases made in March 2012 to prepare for a system conversion were expected to weigh on first-quarter FY2013 platelet growth.
- Management expected the Cell Saver Elite launch to support surgical disposables and anticipated a FY2013 sales mix shift toward higher-margin hospital products. It also expected increased acquisition-integration costs.
- After year-end, Haemonetics agreed to acquire Pall’s blood collection, filtration, and processing product lines for $551 million, subject to closing conditions, with closing expected in FY2013 Q2. The company arranged committed term-loan financing of $475 million; remaining consideration was expected to be funded with cash. It also agreed to acquire Hemerus for up to $27 million, contingent on regulatory approvals, plus royalties on future SOLX product sales.
- The HS Core plasma disposable quality issue led to customer claims. The company estimated a $10.0 million liability, recorded $3.1 million of net FY2012 expense after insurance recovery, and reported a further $3.2 million insurance receivable; recovery of additional amounts remained uncertain.
- Other notable exposures include the OrthoPAT recall, dependence on significant customers (Japanese Red Cross: 13.7% of revenue; Customer B: 11.0%), foreign-exchange movements, regulatory and product-liability risks, and supply-chain concentration. The filing also cites a final Italian subsidiary conviction related to alleged improper payments; a €147,500 fine plus costs was due, with final costs not yet determined.
- The 2.3% U.S. medical-device excise tax was scheduled to begin after December 31, 2012; management was still evaluating its impact. The filing provides no specific consolidated FY2013 revenue or earnings guidance.
Most important facts for investors to verify
- Whether the Pall and Hemerus acquisitions closed on the expected terms and timetable, and the resulting debt, integration costs, and covenant headroom.
- Whether HS Core claims and insurance recoveries changed from the year-end estimates, and whether further product-quality costs arose.
- Whether plasma price reductions and the one-time Japanese Red Cross purchases affected FY2013 growth as management anticipated.
- Whether hospital-product recovery and Cell Saver Elite adoption offset continuing OrthoPAT, surgical-volume, and competitive pressures.
- How customer concentration, foreign exchange, and the medical-device excise tax affected subsequent results and cash generation.